You are viewing the site in preview mode
Skip to main content
|
Diagnosis (WHO 2016)a
|
|
MDS-RS
|
6/14 (43%)
|
|
MDS-SLD
|
4/14 (29%)
|
|
MDS-MLD
|
3/14 (21%)
|
|
MDS-del(5q)
|
1/14 (7%)
|
|
International Prognostic Scoring System (IPSS)
|
|
IPSS score
|
0.3 ± 0.4; 0 (0–1.0)
|
|
Score = 0.0
|
8/14 (57%)
|
|
Score = 0.5
|
3/14 (21%)
|
|
Score = 1.0
|
3/14 (21%)
|
|
Score > 1.0
|
0/14 (0%)
|
|
IPSS risk groups
|
|
Low risk
|
8/14 (57%)
|
|
Intermediate risk 1
|
6/14 (43%)
|
|
Intermediate risk 2
|
0/14 (0%)
|
|
High risk
|
0/14 (0%)
|
|
Cytogenetic based risk classificationb
|
|
Very good
|
0/10 (0%)
|
|
Good
|
9/10 (90%)
|
|
Intermediate
|
1/10 (10%)
|
|
Poor
|
0/10 (0%)
|
|
Very poor
|
0/10 (0%)
|
- Abbreviations: IPSS International Prognostic Scoring System, MDS myelodysplastic syndromes, MDS-del(5q) MDS with isolated deletion of chromosome 5q, MDS-MLD MDS with multilineage dysplasia, MDS-RS MDS with ring sideroblasts, MDS-SLD MDS with single lineage dysplasia, WHO World Health Organization
- Results are expressed as absolute and (relative) frequencies
- a Patients with MDS unclassifiable or with ≥20% blast in the BM were omitted, as did patients with MDS with excess of blasts, and patients diagnosed with Myelodysplastic/myeloproliferative neoplasms
- b Cytogenetic scoring: Very good: -Y, del(11q); Good: normal, del(5q), del(12p), del(20q), double including del(5q); Intermediate: del(7q), + 8, + 19, i(17q), any other single or double independent clones; Poor: −7, inv.(3)/t(3q), del3q, double including − 7/del(7q), complex (3 abnormalities); Very poor: complex (> 3 abnormalities)
